<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01186224</url>
  </required_header>
  <id_info>
    <org_study_id>PHANTASTIC</org_study_id>
    <secondary_id>2009-013798-16</secondary_id>
    <nct_id>NCT01186224</nct_id>
  </id_info>
  <brief_title>Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)</brief_title>
  <acronym>PHANTASTIC</acronym>
  <official_title>A Comparison of Plerixafor/G-CSF With Chemotherapy/G-CSF for Stem Cell Mobilisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and toxicity of plerixafor (AMD 3100) together with
      granulocyte-colony stimulating factor (G-CSF) for stem cell mobilisation, in patients with
      myeloma or lymphoma requiring high dose chemotherapy with stem cell rescue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>A composite primary endpoint of BOTH an adequate stem cell harvest (â‰¥4 x 106 CD34+/kg in no more than 2 aphereses); AND a neutrophil count that never falls below 1.0 x 109 / Litre in the 3 weeks following initiation of mobilisation.</measure>
    <time_frame>3 weeks following initiation of mobilisation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial neutrophil and platelet counts during mobilisation</measure>
    <time_frame>1 Day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total stem cell yield in 1-2 aphereses</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The usage of plerixafor and the number and timing of apheresis collections</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to neutrophil engraftment after subsequent transplantation</measure>
    <time_frame>First of 2 consecutive days on which the neutrophil count equals or exceeds 0.5 x 109/litre</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to platelet engraftment after subsequent transplantation</measure>
    <time_frame>First of two consecutive days on which the platelet count equals or exceeds 50 x 109/litre, having been free of platelet transfusion for at least 48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Dyscrasia</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor and G-CSF</intervention_name>
    <description>G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.
The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All of the following must be satisfied:

        Aged 18 or over

        Able to give informed written consent.

        Diagnosis of EITHER multiple myeloma or related plasma cell dyscrasia, OR any form of
        lymphoma or associated lymphoproliferative disease Autologous stem cell transplantation is
        planned as the next course of treatment.

        The patient has not previously undergone a mobilisation attempt for the current
        transplant. Patients who have received previous autologous transplants at least 2 years
        previously are eligible, as long as stem cell mobilisation has not been attempted for the
        current transplant.

        No serious concomitant illness (e.g. heart disease) that might preclude completion of the
        study.

        Creatinine clearance of at least 30 mls/min. Note that a dose reduction of plerixafor is
        required where the creatinine clearance is between 30-50 mls/min; see section 3.3/5.1/5.3.

        Negative pregnancy test in women of childbearing age.

        Exclusion Criteria:

          -  Unable to give informed written consent

        Pregnancy or lactating

        Creatinine clearance of less than 30 mls/min. Patients with clearances lower than this may
        still be able to receive plerixafor at reduced dosage following discussion with the trial
        co-ordinators, but are not eligible for entry into this trial.

        Any previous attempt at mobilisation for the current transplant. Patients with any form of
        leukaemia, INCLUDING PLASMA CELL LEUKAEMIA, are not eligible.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard E Clark, BA, MB, BS</last_name>
    <phone>0151-706-4297/4344</phone>
    <email>clarkre@liverpool.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Haematology, University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard E Clark, BA, MB, BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>August 20, 2010</lastchanged_date>
  <firstreceived_date>August 18, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Prof. Richard E Clark</name_title>
    <organization>Dept of Haematology, Royal Liverpool University Hospital</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
</clinical_study>
